SSSW(688399)2025-01-24 10:15Financial Performance - The company expects a net profit attributable to shareholders of the parent company for 2024 to be between -2.7 million and -1.8 million, representing a reduction in losses of 371.11 million to 372.01 million compared to the previous year, a year-on-year reduction of 99.28% to 99.52%[3]. - The expected net profit attributable to shareholders of the parent company, excluding non-recurring gains and losses, is projected to be between -75 million and -68 million, indicating a reduction in losses of 354.20 million to 361.20 million compared to the previous year, a year-on-year reduction of 82.53% to 84.16%[5]. - In 2023, the company reported a total profit of -375.67 million, with a net profit attributable to shareholders of the parent company of -373.81 million, and a net profit excluding non-recurring gains and losses of -429.20 million[6]. Cost Management and Efficiency - The company has implemented cost reduction and efficiency enhancement measures, leading to a significant decrease in period expenses and improved profitability potential[7]. - The company has improved asset management efficiency, leading to a significant decrease in impairment losses recognized during the reporting period[9]. Market Conditions - Despite a stable development of the main business, the company faced a decline in sales revenue due to intensified industry competition and ongoing medical procurement, resulting in a decrease in product sales prices[7]. Research and Development - The company continues to prioritize R&D investment, maintaining a relatively high intensity of R&D spending while enhancing the precision management of its R&D system[7]. Earnings Forecast - There are no major uncertainties affecting the accuracy of this earnings forecast, and the forecast has not been audited[10]. - The data provided is preliminary and the final audited financial data will be disclosed in the 2024 annual report[11].